NRXS
Neuraxis, Inc.
NYSE MKT: NRXS · HEALTHCARE · BIOTECHNOLOGY
$7.44
-2.23% today
Updated 2026-04-29
Market cap
$93.54M
P/E ratio
—
P/S ratio
26.21x
EPS (TTM)
$-0.95
Dividend yield
—
52W range
$2 – $8
Volume
0.2M
Neuraxis, Inc. (NRXS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.93M | $2.72M | $2.68M | $2.46M | $2.69M | $3.57M |
| Revenue growth (YoY) | — | +41.0% | -1.3% | -8.4% | +9.2% | +32.9% |
| Cost of revenue | $481089.00 | $467656.00 | $297060.00 | $303345.00 | $362002.00 | $562916.00 |
| Gross profit | $1.45M | $2.25M | $2.39M | $2.16M | $2.32M | $3.01M |
| Gross margin | 75.1% | 82.8% | 88.9% | 87.7% | 86.5% | 84.2% |
| R&D | $166798.00 | $203414.00 | $225610.00 | $169315.00 | $206107.00 | $493611.00 |
| SG&A | $4.88M | $4.56M | $5.12M | $8.33M | $8.95M | $8.06M |
| Operating income | $-4.12M | $-2.97M | $-3.37M | $-6.66M | $-7.16M | $-7.83M |
| Operating margin | -213.5% | -109.1% | -125.6% | -270.9% | -266.5% | -219.4% |
| EBITDA | $-3.61M | $-2.95M | $-4.33M | $-9.23M | $-7.90M | $-7.67M |
| EBITDA margin | -187.3% | -108.6% | -161.1% | -375.1% | -294.2% | -214.8% |
| EBIT | $-3.65M | $-2.99M | $-4.36M | $-9.27M | $-7.94M | $-7.73M |
| Interest expense | $75711.00 | $36928.00 | $417601.00 | $5.36M | $300715.00 | $73969.00 |
| Income tax | $324063.00 | $45200.00 | $429557.00 | $5.36M | $-8.24M | — |
| Effective tax rate | -9.5% | -1.5% | -9.9% | -57.9% | 50.0% | 0.0% |
| Net income | $-3.73M | $-3.03M | $-4.78M | $-14.63M | $-8.24M | $-7.80M |
| Net income growth (YoY) | — | +18.7% | -57.9% | -206.0% | +43.7% | +5.4% |
| Profit margin | -193.0% | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |